Table 4

Detection of CTCs in the peripheral blood of patients with cutaneous malignant melanoma using RT-PCR

Author (Ref.)No. of RT-PCR-positive patients/Total no. of patients tested (%) according to AJCC stagea
I–IIIIIIV
Brossart et al. (76)1/10 (10%)6/17 (35%)29/29 (100%)
Hoon et al. (74) b13/17 (76%)31/36 (86%)63/66 (95%)
Battayani et al. (72)2/10 (20%)22/51 (43%)16/32 (50%)
Foss et al. (77)0/6 (0%)
Pittman et al. (78)3/24 (12.5%)
Kunter et al. (75)0/16 (0%)0/16 (0%)9/34 (26%)
Mellado et al. (79)14/39 (36%)7/17 (41%)33/35 (94%)
Curry et al. (80) c48/160 (30%)60/116 (52%)
  • a Stage I, primary tumor <1.5 mm in thickness with no metastases; stage II, primary tumor >1.5 mm in thickness with no metastases; stage III, regional lymph node metastases; stage IV, distant metastases.

  • b In this study, the peripheral blood was analyzed for four markers (tyrosinase, p97, Muc 18, and MAGE-3).

  • c In this report, the samples were tested for tyrosinase and MART-1. In both articles (74 , 80) , RT-PCR positivity was defined as positivity for any of the markers. In all the other studies listed, tyrosinase alone was used as a marker for melanoma cells.